Last quarter (Q3 2023), Protara Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Protara Therapeutics's net income was $-9.86M. See Protara Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 21.00K	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 21.00K	-	-	-	-	-
Operating Expense	$ 42.56M	$ 67.06M	$ 47.49M	$ 34.44M	$ 7.83M	$ 21.37M
Operating Income	$ -42.56M	$ -67.06M	$ -47.49M	$ -34.44M	$ -7.83M	$ -21.37M
Net Non Operating Interest Income Expense	$ 2.92M	$ 1.11M	$ 237.00K	$ 466.00K	$ 0.00	-
Other Income Expense	$ 22.00K	$ 27.00K	$ 1.74M	-	$ 262.00K	$ 643.00K
Pretax Income	$ -69.15M	$ -65.94M	$ -47.25M	$ -33.98M	$ -7.83M	$ -20.73M
Tax Provision	$ 9.02M	$ -9.02M	$ -4.29M	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -69.15M	$ -65.94M	$ -47.25M	$ -33.98M	$ -7.83M	$ -20.73M
Basic EPS	$ -6.09	$ -5.86	$ -4.21	$ -4.70	$ -2.57	$ -8.10
Diluted EPS	$ -7.73	$ -5.86	$ -4.21	$ -4.70	$ -2.57	$ -8.10
Basic Average Shares	$ 33.96M	$ 11.25M	$ 11.22M	$ 7.23M	$ 5.84M	$ 2.56M
Diluted Average Shares	$ 45.22M	$ 11.26M	$ 11.23M	$ 7.23M	$ 5.84M	$ 2.56M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 42.56M	$ 67.06M	$ 47.49M	$ 34.44M	$ 7.83M	$ 21.37M
Net Income From Continuing And Discontinued Operation	$ -69.15M	$ -65.95M	$ -47.25M	$ -33.98M	$ -7.83M	$ -20.73M
Normalized Income	$ -7.79M	$ -45.46M	-	$ -33.98M	$ -7.83M	$ -21.16M
Interest Expense	-	-	-	$ 34.00K	-	-
EBIT	$ -69.69M	$ -65.94M	$ -37.12M	$ -33.94M	$ -7.83M	$ -21.37M
EBITDA	$ -68.55M	$ -63.18M	$ -34.21M	$ -33.84M	$ -7.81M	$ -21.26M

Currency in USD

Protara Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing